NEW YORK (GenomeWeb News) – CardioDx today announced a deal with Core Diagnostics India for the marketing and sale of CardioDx's coronary artery disease test in India.
Under the terms of the deal, Core will make CardioDx's Corus CAD diagnostic test available to patients in India, which CardioDx said has one of the highest rates of CAD in the world. Blood samples collected for the test will be sent to the Palo Alto, Calif.-based firm's CLIA laboratory for analysis and turnaround.
Corus CAD is a non-invasive blood-based gene expression test for the evaluation of patients with signs and symptoms suggestive of obstructive CAD. The test was launched in 2009 as a laboratory-developed test, and during the summer CardioDx raised $58 million to support its commercialization.
"Coronary artery disease is a rising epidemic in India and about 62 million of the country's population is estimated to suffer from CAD by 2015," Core Diagnostics India CEO Mohan Uttarwar said in a statement. "CardioDx's state of the art Corus CAD gene expression diagnostic test will help us spearhead the personalized medicine movement in India and provide diagnostic technology that is more convenient than current diagnostic tests for CAD … This test will help meet the needs of a new generation of patients in India who insist on individualized, best-in-class medical care."
Core Diagnostics India is a clinical laboratory based in Gurgaon, India.
Financial and other terms of the deal were not disclosed.